21
Participants
Start Date
June 22, 2017
Primary Completion Date
June 8, 2029
Study Completion Date
June 8, 2029
PF-06838435 (formerly SPK-9001)
Gene Therapy: A novel, bioengineered adeno-associated viral vector carrying human factor IX variant
Royal Prince Alfred Hospital, Camperdown
Weill Cornell Medicine - New York Presbyterian Hospital, New York
The Children's Hospital of Philadelphia, Philadelphia
Istanbul Universitesi Onkoloji Enstitusu Çocuk Hematoloji Onkoloji Bilim Dali, Istanbul
Ege Universitesi Tip Fakultesi Cocuk Sagligi ve Hastaliklari Anabilim Dali, Izmir
Mississippi Center for Advanced Medicine, Madison
LA Center for Bleeding and Clotting Disorders - Metairie, Metairie
Tulane Lakeside Hospital, Metairie
LA Center for Bleeding and Clotting Disorders, New Orleans
Tulane University Clinical Translational Unit, New Orleans
Tulane University Hospitals and Clinic, New Orleans
Tulane University School of Medicine, New Orleans
University Medical Center New Orleans, New Orleans
Louisiana Center for Advanced Medicine, Slidell
UC Davis Comprehensive Cancer Center, Sacramento
UC Davis Ellison Ambulatory Care Clinic, Sacramento
UC Davis Medical Center department of Radiology, Sacramento
UC Davis Medical Center, Sacramento
UC Davis Midtown Cancer Center, Sacramento
UC DavisHealth Main Hospital, Sacramento
McMaster University Medical Centre - Hamilton Health Sciences, Hamilton
McGill University Health Center - Research Institute, Montreal
Lead Sponsor
Pfizer
INDUSTRY